Eisai's Zonegran safety in pediatric patients confirmed by pooled data analysis

The safety profile of adjunctive Japanese drugmaker Eisai’s (TYO: 4523) Zonegran (zonisamide) in pediatric patients with partial epilepsy is confirmed by pooled data published in the European Journal of Paediatric Neurology (EJPN).

These newly-published safety data from 17 studies support zonisamide’s proven clinical efficacy in children aged six years and above. Zonisamide is indicated in Europe as adjunctive therapy in the treatment of partial seizures, with or without secondary generalization, in adults, adolescents, and children aged six years and above.

“Selection of the most appropriate treatment approach for children with epilepsy is a challenge as epileptic seizures can often impact a child’s neurological development, as well as physical well-being. This makes well-tolerated treatment options that can be used in this age group, such as zonisamide, valuable for doctors and patients alike,” commented Professor Helen Cross, Great Ormond Street Hospital and Young Epilepsy, UK.